These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 27467716)

  • 1. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
    He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
    PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
    Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
    Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
    Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
    J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
    Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
    Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
    [No Abstract]   [Full Text] [Related]  

  • 7. The feasibility of
    Liu S; Gu B; Zhang J; Zhang Y; Xu X; Yuan H; Zhang Y; Yang Z
    Ann Nucl Med; 2018 May; 32(4):272-280. PubMed ID: 29478216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
    Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
    J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
    Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
    J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
    Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
    Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal
    He S; Wang M; Zhang Y; Luo J; Zhang Y
    Contrast Media Mol Imaging; 2019; 2019():2374565. PubMed ID: 31281233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
    Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
    J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
    Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
    Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
    J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
    Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
    Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
    Evangelista L; Guarneri V; Conte PF
    Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.